ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
  • Abstract Number: 2524

    Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort
  • Abstract Number: 2525

    Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
  • Abstract Number: 2526

    Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
  • Abstract Number: 2527

    Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
  • Abstract Number: 2528

    Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
  • Abstract Number: 2529

    IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features
  • Abstract Number: 2530

    Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
  • Abstract Number: 2531

    Coronary periarteritis in IgG4-Related Disease
  • Abstract Number: 2532

    Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
  • Abstract Number: 2533

    Patterns of skin lesion transcriptomics in different forms of vasculitis
  • Abstract Number: 2534

    Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
  • Abstract Number: 2535

    Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
  • Abstract Number: 2536

    High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
  • Abstract Number: 2537

    Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
  • Abstract Number: 2538

    Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
  • « Previous Page
  • 1
  • …
  • 167
  • 168
  • 169
  • 170
  • 171
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology